Investigator

Bryanna L. Norden

Research Technologist · Massachusetts General Hospital, Cancer Center- Corcoran Lab

Research Interests

BLNBryanna L. Norden
Papers(1)
Ultrasensitive Detect…
Collaborators(10)
Bryant D. MillerConnie WuDavid C ChristianiDavid R. WaltDavid T. TingElyssa N. DenaultEuihye JungGary ChiGeorge EngHua Jiang
Institutions(6)
Massachusetts General…Dana Farber Cancer In…University of MichiganHarvard UniversityUniversity of Pennsyl…Obstetrics And Gyneco…

Papers

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Abstract Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10−17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring. Significance: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring. See related commentary by Doucet and Cristofari, p. 2502. This article is featured in Selected Articles from This Issue, p. 2489

53Works
1Papers
58Collaborators
Drug Resistance, NeoplasmCholangiocarcinomaNeoplasmsBile Duct NeoplasmsBreast NeoplasmsCell Line, TumorTumor Suppressor Protein p53Circulating Tumor DNA

Positions

2020–

Research Technologist

Massachusetts General Hospital · Cancer Center- Corcoran Lab

Education

2020

Bachelor of Science

Stonehill College · Biology